McCune C S, Henshaw E C, Marquis D M, Sahasrabudhe D, Leary J, O'Donnell R W
J Biol Response Mod. 1987 Apr;6(2):130-40.
Human hybrid tumor cells have been produced by fusing cells from freshly harvested tumor specimens with cells from a cultured human tumor line, D98OR. Fusions were performed with cells from 67 tumors and continuously growing hybrid lines were obtained from 16 (24%). A successful fusion usually produced 1 or 2 hybrid lines, but four easily fusable tumors produced from 6 to 26 lines. The parent cells and hybrids were analyzed by flow cytometry. Hybrids appeared to retain a high percentage of parental deoxyribonucleic acid. Ten patients participated in a clinical study in which they received intradermal immunization with semiautologous hybrids and Corynebacterium parvum as adjuvant. The only side effect was slight local tenderness at the injection sites. No tumor regressions occurred. Skin testing with parental and hybrid cells was performed prior to and following immunization with hybrids. Delayed cutaneous hypersensitivity was often achieved for hybrids but not for autologous tumor cells.
通过将新鲜采集的肿瘤标本中的细胞与培养的人肿瘤细胞系D98OR的细胞融合，已产生了人杂交肿瘤细胞。用来自67个肿瘤的细胞进行融合，从16个（24%）中获得了持续生长的杂交细胞系。一次成功的融合通常产生1或2个杂交细胞系，但有4个易于融合的肿瘤产生了6至26个细胞系。通过流式细胞术分析亲代细胞和杂交细胞。杂交细胞似乎保留了高比例的亲代脱氧核糖核酸。10名患者参与了一项临床研究，他们接受了半自体杂交细胞的皮内免疫，并以短小棒状杆菌作为佐剂。唯一的副作用是注射部位有轻微的局部压痛。没有发生肿瘤消退。在用杂交细胞免疫之前和之后，用亲代细胞和杂交细胞进行了皮肤试验。杂交细胞常常能引发迟发性皮肤超敏反应，但自体肿瘤细胞则不能。
